Description

Azvudine Tablets (Jiebei’an) 1?mg are synthetic nucleoside analog tablets designed to inhibit viral reverse transcriptase and RNA-dependent RNA polymerase (RdRp) in research models of viral infection. Initially developed for hepatitis C and HIV, and conditionally approved in China for COVID-19 treatment, it shows potent activity in laboratory settings against RNA viruses. Manufactured to pharmaceutical standards under license H20210035 by Beijing Xiehe Pharmaceutical Co., Ltd. Each bottle contains 35 tablets of 1?mg each. Intended only for laboratory research and preclinical studies.

Product Specifications

Mechanism of Action & Research Applications

Azvudine Tablets (Jiebei’an) function as a synthetic antiviral nucleoside analog that inhibits viral reverse transcriptase and RdRp, leading to premature termination of viral RNA synthesis. It may also modulate immune response via thymus targeting and cytokine balance. In research, Azvudine Tablets (Jiebei’an) are used to investigate antiviral efficacy in models of HIV, hepatitis, and coronavirus infections, explore mechanisms of viral resistance, study viral kinetics, and evaluate combination antiviral therapies. Strictly for laboratory and preclinical research use.

Side Effects (For Reference Only in Models)

In experimental settings, observed side effects may include mild dizziness, nausea, elevated liver enzyme markers, potential hepatotoxicity, fatigue-like response, and occasional transient fever. Monitoring of liver function and hematologic parameters is advised in research models. These findings serve as guidance for experimental dose safety.

Disclaimer

Azvudine Tablets (Jiebei’an) 1?mg are strictly intended for laboratory research use only. Not for human or veterinary therapeutic use.